drugset

drugset / Trial / NCT05872204

Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer

NCT05872204 ↗

Phase 2 Recruiting 100 enrolled Universitaire Ziekenhuizen KU Leuven Eli Lilly and Company · collab European Network of Gynaecological Oncological Trial Groups (ENGOT) · collab Kom Op Tegen Kanker · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the efficacy and safety of abemaciclib and letrozole for treatment of estrogen receptor-positive rare ovarian cancer.

Timeline

Start: 2023-11-30
Primary completion: 2028-01
Completion: 2028-01

Publications

Ottenbourgs T, van Gorp T, Kridelka F, Baert T, Denys H, Selle F, Baas I, Van Rompuy AS, Lambrechts D, Van Nieuwenhuysen E. A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trial. Int J Gynecol Cancer. 2024 Apr 1;34(4):627-630. doi: 10.1136/ijgc-2023-005189.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Abemaciclib	Small molecule	150 mg	Oral
Subject	Letrozole	Other / unclassified	2.5 mg	Oral

Indications